The importance of angiogenesis in the development of tumors and metastases in breast cancer is well established[1]. Interrupting this process has been considered a promising therapeutic option, initially focusing on metastatic disease[2]. The most extensively studied strategy in anti-angiogenic treatment consists of blocking the vascular endothelial growth factor (VEGF) using the monoclonal antibody bevacizumab. Bevacizumab received FDA approval for metastatic breast cancer in 2008 after it was shown to nearly double progression-free survival (PFS) in combination with chemotherapy over chemotherapy alone in the first line setting[3,4].
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2iDUOmN
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
Publication date: Available online 4 January 2018 Source: European Journal of Radiology Author(s): Peiyao Zhang, Jing Wang, Qin Xu, Zhen...
-
Background Hyperthyroidism is associated with increased thrombotic risk. As contact system activation through formation of neutrophil extrac...
-
Abstract Bone homeostasis is maintained by a balance between resorption of the bone matrix and its replacement by new bone. Osteoclasts p...
-
Abstract Continuous tooth replacement is common for tetrapods, but some groups of acrodont lepidosaurs have lost the ability to replace th...
-
from Imaging via alkiviadis.1961 on Inoreader http://ift.tt/2God5y1
-
ACS Nano DOI: 10.1021/acsnano.6b07537 from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2i580k9 via...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου